The overall mortality rate for U.S. patients with cardiovascular disease has improved significantly in recent years. At the ...

Enoumena Therapeutics Inc. and AOP Health today announced an exclusive commercialization agreement to expand Canadian ...

Despite sustained declines in overall cardiovascular disease mortality in the U.S., disparities based on race, ethnicity and ...

Despite sustained declines in overall cardiovascular disease mortality in the U.S., disparities based on race, ethnicity and ...

A specialist in diabetes and endocrinology thoroughly examines the evidence from the latest 2026 meta-analysis. Why do 'fish ...

Cardiovascular disease (CVD) mortality rates in the United States substantially decreased between 2000 and 2019, but the pace ...

Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved an additional indication for Jaypirca (pirtobrutinib, 100 mg & 50 mg tablets), a ...

Nature MedicinePulsed field ablation (PFA) has rapidly changed the landscape of atrial fibrillation ablation.The procedure is ...

FDA expands pirtobrutinib into first-line CLL/SLL for adults without 17p deletion, delivering major PFS gains versus ...

FDA expanded pirtobrutinib into frontline CLL/SLL for patients without del(17p), establishing a noncovalent BTK inhibitor option earlier in the treatment sequence. BRUIN CLL-313 demonstrated ...

Orforglipron met expectations in ACHIEVE-4, with cardiovascular benefit yet to be proven ...

Eli Lilly's noncovalent BTK inhibitor Jaypirca has been cleared by the FDA in its first frontline indication for chronic ...